Diabetes Mellitus, published by the Endocrinology Research Centre in the Russian Federation, is an esteemed open-access journal dedicated to the field of endocrinology, diabetes, and metabolism. Since its inception in 1998, this journal has been a pivotal platform for disseminating cutting-edge research and comprehensive reviews that address the multifaceted challenges posed by diabetes. With its current quartile ranking of Q4 in Endocrinology and the associated fields, as well as commendable involvement in the broader scope of Internal Medicine, Diabetes Mellitus plays a crucial role in enhancing clinical practices and informing innovative therapeutic strategies. The journal caters to a diverse audience of researchers, healthcare professionals, and students, particularly those seeking to expand their knowledge and improve patient outcomes in diabetes care. With a commitment to fostering scientific conversation and collaboration, Diabetes Mellitus is an invaluable resource for anyone engaged in the fight against diabetes and its complications.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

Diabetologie is a dedicated academic journal published by Springer Heidelberg, focusing on the diverse fields of endocrinology, diabetes, and metabolism. With the ISSN 2731-7447 and E-ISSN 2731-7455, this journal serves as a significant platform for the dissemination of innovative research and evidence-based practices within the rapidly evolving landscape of diabetes care and management. Although currently not classified as Open Access, the journal provides robust subscription options that grant access to a wealth of peer-reviewed articles, making it an invaluable resource for researchers and practitioners alike. With an H-index that reflects its emerging influence and a Scopus ranking in the 10th percentile within its category, Diabetologie aims to elevate the scientific understanding of diabetes through rigorous scholarship. The journal captures the latest findings and clinical advancements from 2022 to 2024, placing a particular emphasis on novel therapeutic strategies and technological innovations. By fostering a collaborative environment dedicated to the improvement of diabetes outcomes, Diabetologie stands as a crucial contributor to the global dialogue on diabetes treatment and research.

DIABETIC MEDICINE is a leading peer-reviewed journal published by Wiley, dedicated to advancing the field of endocrinology, specifically focusing on the pathophysiology, management, and prevention of diabetes mellitus and its complications. With an impressive impact factor reflecting its significant role in shaping clinical practice and research, DIABETIC MEDICINE holds a prominent position among its peers, categorized in the Q1 quartiles for Endocrinology, Diabetes and Metabolism, and Internal Medicine. Since its inception in 1984, the journal has provided a platform for rigorous and innovative research, fostering collaborative efforts among researchers, clinicians, and students to enhance diabetes care. The journal is esteemed for its high-ranking performance in Scopus, highlighted by its ranking of #33 in Internal Medicine and #64 in Endocrinology, Diabetes, and Metabolism. By offering insightful access to groundbreaking studies and reviews, DIABETIC MEDICINE plays a crucial role in informing policy and improving medical outcomes for individuals with diabetes, making it an essential resource for those in medical and clinical research fields.

Journal of Endocrinology and Metabolism is a dynamic and essential publication in the field of endocrinology, diabetes, and metabolism, published by ELMER PRESS INC in Canada. With an ISSN of 1923-2861 and E-ISSN 1923-287X, this journal serves as a pivotal platform for sharing innovative research and advancements from 2018 through 2024. Although categorized in the fourth quartile (Q4) for 2023, its commitment to high-quality research is reflected in its ongoing efforts to foster scholarly dialogue and illuminate critical issues within its scope. Targeting primarily researchers, healthcare professionals, and students, the journal aims to disseminate crucial findings that advance our understanding of endocrine functions and metabolic processes. Given its Scopus ranking of #207 out of 244 within its category, the Journal of Endocrinology and Metabolism continues to contribute to the global discourse on these vital health topics.

Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.

Current Diabetes Reports is a leading academic journal published by CURRENT MEDICINE GROUP, dedicated to advancing research and clinical practices in the field of diabetes and endocrinology. With an impressive impact factor and ranked in the prestigious Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 2001 and converging years up to 2024, Current Diabetes Reports aims to disseminate high-quality, peer-reviewed research articles, reviews, and clinical studies that address the multifaceted challenges of diabetes management and treatment. As it continues to thrive within a robust international community, the journal provides critical insights that are essential for improving patient outcomes and informing public health policies in the United States and beyond.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.